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Abstract – 246 words 
Objectives: This study aimed at re-evaluating the strength and shape of the dose-response 
relationship between the combined (or joint) effect of intensity and duration of cigarette smoking 
and the risk of head and neck cancer (HNC). We explored this issue considering bivariate spline 
models, where smoking intensity and duration were treated as interacting continuous exposures.  
Materials and Methods: We used individual-level pooled data from 33 case-control studies 
(18,260 HNC cases and 29,844 controls) participating in the International Head and Neck 
Cancer Epidemiology (INHANCE) consortium. In bivariate regression spline models, exposures 
to cigarette smoking intensity and duration (compared with never smokers) were modeled as a 
linear piecewise function within a logistic regression also including potential confounders. We 
jointly estimated the optimal knot locations and regression parameters within the Bayesian 
framework. 
Results: For oral-cavity/pharyngeal (OCP) cancers, an odds ratio (OR) >5 was reached after 30 
years in current smokers of ~20 or more cigarettes/day. Patterns of OCP cancer risk in current 
smokers differed across strata of alcohol intensity. For laryngeal cancer, ORs>20 were found for 
current smokers of ≥20 cigarettes/day for ≥30 years. In former smokers who quit ≥10 years ago, 
the ORs were approximately halved for OCP cancers, and ~1/3 for laryngeal cancer, as 
compared to the same levels of intensity and duration in current smokers.  
Conclusion: Referring to bivariate spline models, this study better quantified the joint effect of 
intensity and duration of cigarette smoking on HNC risk, further stressing the need of smoking 
 8 
cessation policies. 
 
Keywords: bivariate spline models; cigarette smoking duration; cigarette smoking intensity; 
head and neck cancer; INHANCE; laryngeal cancer; oral cavity and pharyngeal cancers. 
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Introductiona 
In recent years, tobacco smoking has confirmed its role as the worldwide leading cause of 
preventable diseases and death. It is responsible for at least 12% of all deaths and of 22% of all 
cancer deaths worldwide [1]. Tobacco has been strongly associated with head and neck cancer 
(HNC, i.e., cancers of the oral cavity, pharynx, and larynx), which is the sixth most common 
cancer type, accounting for nearly 900,000 new cases in 2018 [2]. 
A dose-response relationship with HNC risk has been reported for smoking intensity 
(cigarettes per day reported during the exposure period) and duration (years of exposure), as 
well as for a cumulative smoking exposure measured in pack-years [3,4]. Compared with 
intensity, smoking duration was shown to provide a greater risk of developing HNC [5,6], as well 
as, other tobacco-related cancers, such as lung [7,8] and bladder cancers [9,10]. 
So far, the association between tobacco smoking and HNC risk was evaluated by considering 
duration and intensity as either separate or interacting predictors. In the latter case, the 
combined exposure was modeled as either cross-product or pack-years [6,11,12]. Step-functions 
[4, page 369] were widely used to provide risk estimates for the cross-product of the categorized 
exposures. This approach assumed a constant rate within each combined category of exposure; 
however, this assumption may have been too rough and/or leading to some efficiency loss [13-
15]. As an alternative, linear-exponential models estimated the excess odds ratio (OR) of HNC 
                                                                
a Abbreviations: CI: credible interval; HNC: head and neck cancer; INHANCE: International Head and 
Neck Cancer Epidemiology; NUTS: No-U-Turn Sampler; OCP: oral cavity and pharynx; OR: odds ratio; 
WAIC: Wanatabe-Akaike Information Criterion. 
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within models including pack-years and smoking intensity [6,9]. The pack-year approach was 
traditionally based on a strong assumption about the effects of smoking intensity and duration; 
for instance, the effect of smoking ½ pack per day (10 cigarettes) for 40 years was equivalent to 
smoking 2 packs (40 cigarettes) per day for 10 years. Indeed, both of them reflect a cumulative 
exposure of 20 pack-years [16]. However, the 2 exposures were measured on different metrics. 
Bivariate spline models have the potential to provide a more realistic representation of the 
association between smoking intensity and duration and HNC risk [15]. First, they allow to model 
intensity and duration in their original scale of continuous exposures and, in this aspect, splines 
outperform step-function models. Second, the two exposures are allowed to determine disease 
risk in their separate or interacting role. Third, a non-linearity in the dose-response relationship 
may be modeled. 
This study re-evaluated the joint effect of intensity and duration of tobacco smoking on HNC 
risk, by means of bivariate spline models, within the International Head and Neck Cancer 
Epidemiology (INHANCE) consortium [11]. 
 
Materials and methods 
Data source 
The INHANCE consortium was established in 2004 to elucidate the etiology of HNC through 
pooled analyses of individual-level data from several studies on a large scale [11]. Several 
aspects of tobacco smoking and HNC risk have been previously investigated within the 
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consortium [5,6,11,17-19]. 
From the INHANCE consortium pooled dataset (version 1.5), we extracted all the available 
case-control studies (35 studies) that collected information on cigarette smoking status, intensity, 
and duration at individual level (http://www.inhance.utah.edu, last accessed March 25th, 2019). 
Available data were harmonized at the study coordinating center [11]. In all the studies, 
information on smoking history was self-reported. While different studies had used different 
definitions of smoking status, the current study defined as never smokers those individuals who 
never smoked regularly, or smoked for a very short period, i.e., less than 12 months [11]; likewise, 
former smokers were defined as those who had abstained from any type of smoking since at 
least 12 months before cancer diagnosis (cases) or interview (controls).  
Details on individual studies, data harmonization, and pooling methods are summarized in 
eTable 1. Informed consent was obtained from all study subjects. The investigations were 
approved by the relevant Boards of Ethics, according to the regulation in force at data collection 
time. 
Selection of subjects 
The INHANCE protocol allowed inclusion of invasive cancer cases of the oral cavity, 
oropharynx, hypopharynx, oral cavity or pharynx not otherwise specified, larynx, or unspecified 
HNC. Cases with cancers of the salivary glands or of the nasal cavity/ear/paranasal sinuses 
were excluded [11]. The original study sample included 25,865 HNC cases and 37,248 controls, 
giving a total of 63,113 subjects. 
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We conducted subjects’ selection according to the following main steps (eAppendix, text and 
Figure 1), excluding: 1. cases with unspecified (95 subjects) or overlapping HNC (331 subjects); 
2. subjects reporting smoking tobacco products other than cigarettes (i.e., cigar, pipe, and 
cigarillo), to avoid risk distortion due their use [5] (6,255 subjects); 3. subjects with missing 
information on duration and/or intensity of cigarette smoking (1,897 subjects); 4. all subjects from 
studies that included only never (i.e., Japan 1988-2000) (822 subjects) or current (i.e., France 
1987-1992) smokers (457 subjects), after the previous selection steps. 
In order to prevent potential estimation distortion at the highest levels of the exposure 
distributions (due to small numbers of subjects or information bias in heavy tobacco consumers), 
further excluded were those subjects reporting the highest 5% of cigarette smoking intensity (>40 
cigarettes per day) or duration (>51 years) (14% HNC cases and 6% controls excluded). 
After all the described selection steps (eAppendix, text and Figure 1), the analysis included 33 
studies [20-53] with 48,104 subjects (18,260 HNC cases and 29,844 controls) (Table 1). When a 
study reported to have conducted a case-control matching, separate sets of controls were 
matched for oral cavity and pharynx (OCP) cancers combined and for laryngeal cancer cases. In 
detail, the analysis included: 5,423 cancers of the oral cavity; 6,261 pharyngeal cancer cases 
(4,648 oropharyngeal and 1,613 hypopharyngeal cancers cases); 1,633 unspecified oral 
cavity/pharynx cancers (giving a total of 13,317 OCP cancer cases combined), and 4,943 
laryngeal cancers. 
Statistical analysis 
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The bivariate regression spline models [54] used to investigate the dose–response 
relationship between HNC and the joint exposure to smoking intensity and duration was 
described extensively in eAppendix – Statistical Analysis and in Di Credico’s PhD Thesis [55]. 
We assumed a generalized semi-parametric logistic regression model where the two exposures 
were entered as a joined piecewise polynomial of a linear degree with constraints for continuity 
at each join point (called knot), together with potential confounders (i.e., age, sex, race, study, 
education, drinking status, drinking intensity, and drinking duration) [15]. Knots represented 
change points in the slope of the risk surface. The set of spline regression parameters described 
the shape of the risk surface. We further assumed that the knot locations for any of the two 
exposures were unknown parameters to be estimated, up to a maximum of 2 knots allowed for 
each exposure. At the maximum level of complexity, the risk surface was allowed to have 2 
change-points in the slope for any exposure and 9 different areas with a possibly changing slope. 
The optimal knot locations and regression parameters were jointly estimated within the 
Bayesian approach. Prior distributions expressed a priori knowledge (here vague) on plausible 
values of knot locations and regression parameters [56,57]. Their posterior distribution combined 
prior information and available data through the Bayes theorem. A joint posterior distribution was 
simulated for each cancer site, smoking-status stratum (current/former smokers), and 
combination of number of knots using the Markov Chain Monte Carlo-type NUTS (No-U-Turn 
Sampler) [58] algorithm. For each combination of site and stratum, the best model was selected 
among the convergent models with sensible knot locations (≤95th percentile of either exposures) 
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as the one that minimized the Wanatabe-Akaike Information Criterion (WAIC) [59,60]. The 
optimal knot locations, the ORs, and their 95% credible intervals (CIs) were derived from the 
posterior distribution corresponding to the best model. The ORs were presented through three-
dimensional mesh plots that displayed the surface of risk for any combination of cigarette 
smoking intensity and duration, and through two-dimensional contour plots that showed iso-risk 
curves identifying the combinations of the two exposures with the same OR. Also explored were 
trade-offs between intensity and duration in two-dimensional contour plots by comparison of ORs 
for a fixed cumulative exposure (i.e., pack-years). 
To evaluate potential modifying effects of some covariates, analyses were carried out in strata 
of alcohol drinking intensity (i.e., <1, 1-<5, ≥5 drinks per day) for current smokers, and years 
since quitting (i.e., <10, ≥10 years) for former smokers. Separate results for the risk of laryngeal 
cancer across alcohol drinking intensity strata were presented, due to absence of heterogeneity 
of the risk surfaces across strata for current smokers. As a comparison, risk estimates were 
further estimated according to the Bayesian step-function regression model.  
When possible, all the models were fitted with the full set of potential confounders shown in 
Table 1; moreover, ‘‘Never smokers’’ were assumed as the reference category. Calculations were 
carried out using the open-source Stan program [61] within the open-source R program [62,63]. 
 
Results 
Table 1 shows selected characteristics of cases and controls, according to the variables 
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included in the models as potential confounders. Approximately 70% of the subjects were white. 
Studies from Europe contributed with approximately 44% of subjects; 31% of subjects were from 
the United States, whereas the remaining ones were from Latin America (14%) and Asia (11%). 
Six studies provided only cases of OCP cancer. 
Table 2 shows the distribution of cigarette smoking habits for OCP cancer, laryngeal cancer, 
and controls. Never smokers were 21% of OCP and 7% of laryngeal cancers, versus 45% of 
controls. Current smokers were 66% of laryngeal cancer cases, 57% of OCP cancer cases, and 
26% of controls. The prevalence of former smokers was similar in cases and controls, but the 
percentage of subjects who quit cigarette smoking ≥10 years ago was ~52% among HNC cases 
and 72% among controls. 
Figure 2 shows the mesh and contour plots for cancers of the OCP and larynx among current 
cigarette smokers. Knot locations were indicated by thicker black lines; the intersections of the 
lines defined the areas where the risk surface had different slopes. For both cancer sites, the 
best model was characterized by one knot for duration (at 33 years for OCP cancer and 30 years 
for laryngeal cancer) and one knot for intensity (at 16 and 25 cigarettes/day, respectively). 
Smoking duration modified OCP cancer risk at any levels of intensity (Figure 2A). In contrast, for 
any duration up to 10 years, the ORs were always <2, regardless of the intensity of cigarette 
smoking. In addition, at a fixed value of 20 pack-years, an intensity of 40 cigarettes/day and a 
duration of 10 years led to an OR of ~2, whereas the OR was equal to ~4 with a duration of 40 
years in smokers of 10 cigarettes/day. 
 16 
For laryngeal cancer, ORs>20 were found for intensities of >20 cigarettes/day and durations 
of >28 years (Figure 2B). Moreover, ORs>10 of laryngeal cancer were reached by current 
smokers of >20 cigarettes/day only when duration was >20 years; however, ORs>10 were not 
reached for any duration <15 years and any level of intensity. Finally, the OR was 6.2 for 
smokers of 40 cigarettes/day for 10 years, but it was higher (between 9 and 10) for 20 
cigarettes/day smoked for 20 years, or for 10 cigarettes/day smoked for 40 years. 
The shape of the risk surface and the values of the ORs were also very similar across major 
OCP cancer subsites  (i.e., oral cavity and oropharyngeal cancers) (eFigure 2). 
Figure 3 shows the joint effect of current smoking intensity and duration in strata of alcohol 
consumption. Among never drinkers (<1 drink/day), the shape of the risk surface was similar to 
the one presented for all alcohol intensities together (Figure 2A), but the ORs were generally 
lower; all the ORs were < 2 for durations ≤15 years and any intensity, whereas an OR>5 was 
observed only after ~25 years of duration or more (Figure 3A). However, the shape of the surface 
and/or the ORs of the joint effect of duration and intensity were different when light (Figure 3B) 
and heavy (Figure 3C) drinkers were considered. 
As a comparison, the ORs and their corresponding 95% CIs were estimated for each cancer 
site in current smokers within the Bayesian logistic regression model that assumed the presence 
of step functions (Table 3, main ORs). These estimates were compared with the range of OR 
estimates derived from the spline models for each joint category of duration and intensity (Table 
3, bracketed ORs). For both cancer sites, all Min-Max ranges included the OR estimates 
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obtained from the Bayesian logistic regression, and this replication reassured that the spline 
model was valid. In addition, within the examined categories, the step-function intervals widely 
overlapped with the Min-Max ranges of the ORs from the spline models, but failed to capture the 
ORs variability. For instance, for OCP cancer in current smokers of 26-40 cigarettes/day for 36-
51 years, the categorical OR was 8.4 (95% CI: 8.0-8.9), whereas the OR varied from 7.1 to 10.6 
under the spline model approach for the same combined category (Table 3). The same pattern 
emerged at any combination of duration and intensity for both cancer sites for former smokers 
who quit ≥10 years ago (eTable 2).  
Among former smokers who quit ≥10 years ago, no ORs>4 were observed for OCP cancer 
(Figure 4A), and the ORs were approximately halved, as compared to the same levels of 
duration and intensity in current smokers (Figure 2A). A mean risk reduction of 2/3 was also 
found for laryngeal cancer in long-term former smokers, with ORs declines that varied from 1/3 to 
4/5 depending on the different combinations of intensity and duration (Figure 4B). These 
estimates were derived from models that included one knot for intensity (27 cigarettes/day) for 
laryngeal cancer and no knots for OCP cancer. Results on the combined set of former smokers 
(regardless of time since quitting) were similarly presented in eFigure 3. 
 
Discussion 
Our large pooled analysis showed that cigarette smoking duration and intensity did not 
increase HNC risk to the same extent, but the effect was greater for longer durations. At the 
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highest combined levels of cigarette intensity and duration, subjects may reach ORs>10 of OCP 
cancer and ORs>40 of laryngeal cancer, as compared to never smokers. Bivariate regression 
spline models have been proven successful in exploring the separate and joint effects of intensity 
and duration of cigarette smoking. Therefore, when possible, models that allow this differential 
impact of intensity and duration on the risk should be considered [8,12,16]. 
Results from the present study were consistent with previous findings showing no threshold 
effect on HNC risk of shorter durations or lower intensities of tobacco smoking [13,64]. Indeed, 
the literature supported the presence of a dose-response relationship between cigarette smoking 
and HNC risk over the entire range of consumption [5,13]. Our contribution additionally 
suggested that the dose-response relationship with OCP and laryngeal cancer risk was still far 
from being linear, with a steeper increase for intermediate consumptions and a possible plateaux 
indicating a ‘saturation effect’ in smokers with >20 years of duration and >30 cigarettes/day. 
Our results also strengthen the evidence [18,65] on the impact of smoking cessation on HNC 
cancer risk, with the OR in former smokers who quit ≥10 years ago being more than halved for 
OCP cancer and ~1/3 lower for laryngeal cancer, in comparison with current smokers. These 
results convey to the general population and to public health professionals the valuable message 
that it is never too late to give up cigarette smoking, as quitting provides far smaller risks of 
developing HNC cancer for OCP and, most of all, for laryngeal cancers. This is in accordance 
with another recently published meta-analysis of observational studies on laryngeal cancer 
based on 14,292 cases from 3 cohort and 15 case-control studies [65]. 
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When the combined effect of smoking intensity and duration was modelled as a cross-product 
term, an interaction term between alcohol consumption and cigarette smoking was traditionally 
added to the models [3,4]. In our study this effect was explored by stratified regression spline 
models estimated within categories of alcohol consumption; we compared the shape of the risk 
surface and the ORs values from the iso-risk curves across the three stratified analyses. 
However, our results also showed that alcohol acts as a substantial modifier of the association 
between OCP cancer risk and the joint effect of cigarette intensity and duration [4,17]. 
Major strengths of our study included a large sample size, international representativeness, 
and valid information on potential confounding factors. In addition, we applied a novel Bayesian 
approach to jointly estimate the optimal knot locations and the ORs of HNC for the joint effect of 
intensity and duration in a bivariate context. After examining various frequentist solutions [66,67], 
we opted for the Bayesian approach that allowed to put the knots where the data suggested, 
once we had taken the entire set of confounding variables into consideration. Within the 
Bayesian framework, we were also able to choose the optimal number of knots (up to 2) and 
knot locations by model comparison based on information criteria, instead of just comparing 
models with fixed number and location of the knots. Finally, we could incorporate in the model 
selection process evidence from the literature on the maximum number of changes in the risk 
pattern, which is unlikely to be higher than 2. Indeed, cigarette smoking is supposed to have a 
protective or null effect on the risk at lower levels, a saturation effect at the highest intensity 
levels [68], as well as the expected increase previously described at the intermediate levels of 
 20 
consumption. The proposed Bayesian approach is applicable to other epidemiologic scenarios 
where continuous exposures in their potential interaction affect disease risk. 
Among study limitations, the retrospective study design and the self-reported smoking history 
were the most relevant ones. Even if a large amount of literature has suggested acceptable 
correlations between self-reported smoking intensity and cotinine levels in blood or urine [69], 
inaccurate self-reporting may occur. Discrepancies between self-reported and objective 
information were more likely among long-term heavy smokers [70]; higher values of intensity and 
duration were therefore more prone to inaccurate reporting. Furthermore, smoking intensity may 
have varied over time and by age of exposure. However, its estimates were often based on the 
self-reported average number of cigarettes per day; these two aspects may have led to 
appreciable errors in measuring the true mean intensity of exposure over one’s lifetime. These 
issues may well be serious here, given the continuous nature of the exposures considered in 
spline models. To reduce information bias and residual confounding at the extreme values of the 
exposure distributions, we excluded subjects reporting higher (>95th percentiles) cigarette 
intensity and/or duration from the present analysis [13,15,71]. In addition, to avoid bias due to the 
use of other tobacco products, we excluded subjects reporting use of tobacco products other 
than cigarettes. We were also obliged to combine different subsites of OCP cancer, although 
differences in aetiology (i.e., the causal role of human papillomavirus in oropharyngeal cancer) 
have been demonstrated [34]. However, results were similar for major subsites, although based 
on less stable models. Finally, our Bayesian approach was computationally time consuming, 
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asking for several hours of server computing for each model fitted. 
Results from the present study confirmed previous evidence on the main contribution of 
cigarette smoking duration in influencing HNC risk and on the important reduction in HNC risk 
observed in former smokers who quit ≥10 or 15 years ago. Both results strongly support an even 
wider diffusion of public interventions to encourage smokers to quit and help them succeed. 
 22 
 
Acknowledgements: The authors would like to thank Xavier Castellsagué who collected data in 
the IARC International Multicenter study and passed away in 2016. We thank Mrs Luigina Mei for 
editorial assistance.  
Funding: This work was supported by grants from the: National Institutes of Health (NIH) [no 
grant number provided for the INHANCE Pooled Data Project, grant numbers P01CA068384, 
K07CA104231 for the New York Multicenter study, grant numbers R01CA048996, 
R01DE012609 for the Seattle (1985-1995) study, grant number TW001500 for the Fogarty 
International Research Collaboration Award (FIRCA) supporting the Iowa study, grant number 
R01CA061188 for the North Carolina (1994-1997) study, grant numbers P01CA068384, 
K07CA104231, R01DE013158 for the Tampa study, grant numbers P50CA090388, 
R01DA011386, R03CA077954, T32CA009142, U01CA096134, R21ES011667 for the Los 
Angeles study, grant  numbers R01ES011740, R01CA100264 for the Houston study, grant 
numbers R01CA078609, R01CA100679 for the Boston study, grant number R01CA051845 for 
the MSKCC study, grant number R01CA030022 for the Seattle-Leo study, grant number 
DE016631 for the Baltimore study]; National Cancer Institute (NCI) at the National Institutes of 
Health (NIH) [grant number R03CA113157 for the INHANCE Pooled Data Project, no grant 
number provided for the Intramural Programs supporting the Puerto Rico and the US Multicenter 
studies, grant number R01CA90731-01 for the North Carolina (2002-2006) study]; National 
Institute of Dental and Craniofacial Research (NIDCR) at the National Institutes of Health (NIH) 
 23 
[grant number R03DE016611 for the INHANCE Pooled Data Project, grant numbers 
R01DE011979, R01DE013110 for the Iowa study, no grant number provided for the Intramural 
Program supporting the Puerto Rico study]; Italian Association for Research on Cancer (AIRC) 
[no grant number provided for the Milan (1984-1989) study, for the Aviano study, for the Italy 
Multicenter study and for the Rome study, grant number 10068 for the Milan study (2006-2009)]; 
Italian League against Cancer [no grant number provided for the Aviano and Italy Multicenter 
studies]; Italian Ministry of Research [no grant number provided for the Aviano and Italy 
Multicenter studies]; the Swiss Research against cancer/Oncosuisse [grant numbers KFS-700, 
OCS-1633 for the Swiss study]; World Cancer Research Fund [no grant number provided for the 
Central Europe study]; European Commission [grant number IC18-CT97-0222 (INCO-DC 
Program) for the Latin America study, grant number IC15-CT98-0332 (INCO-COPERNICUS 
Program) for the Central Europe study]; Veterans Affairs Merit Review Funds [no grant number 
provided for the Iowa study]; National Institute of Environmental Health Sciences (NIEHS) [grant 
number P30ES010126 for the North Carolina (1994-1997) study, grant number P30ES010126 
for the North Carolina (2002-2006) study]; Alper Research Program for Environmental Genomics 
of the UCLA Jonsson Comprehensive Cancer Center [no grant number provided for the Los 
Angeles study]; Fondo para la Investigacion Cientifica y Tecnologica Argentina (FONCYT) [no 
grant number provided for the Latin America study]; Institut Hospital del Mar d’Investigacions 
Mediquès (IMIM) [no grant number provided for the Latin America study]; Fundação de Amparo 
à Pesquisa no Estado de São Paulo (FAPESP) [grant number 01/01768-2 for the Latin America 
 24 
study, grant numbers GENCAPO 04/12054-9, 10/51168-0 for the Sao Paulo study]; Fondo de 
Investigaciones Sanitarias (FIS) of the Spanish Government [grant number FIS 97/0024, FIS 
97/0662, BAE 01/5013 for the International Multicenter study]; International Union Against 
Cancer (UICC) [no grant number provided for the International Multicenter study]; Yamagiwa-
Yoshida Memorial International Cancer Study Grant [no grant number provided for the 
International Multicenter study]; European Community (5th Framework Programme) [grant 
number QLK1-CT-2001-00182 for the Western Europe study]; Ministry of Science, Research and 
Arts Baden-Wurttemberg [no grant number provided for the Germany-Saarland study]; German 
Ministry of Education and Research [grant number 01GB9702/3 for the Germany-Heidelberg 
study]; Scientific Research grant from the Ministry of Education, Science, Sports, Culture and 
Technology of Japan [grant number 17015052 for the Japan (2001-2005) study]; Third-Term 
Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor and 
Welfare of Japan [grant number H20-002 for the Japan (2001-2005) study]; Johns Hopkins 
Richard Gelb Cancer Prevention Award [no grant number provided for the HOTSPOT study]; 
Italian Foundation for Cancer Research (FIRC) [no grant number provided for the Milan study 
(2006-2009)]; Italian Ministry of Education - PRIN 2009 Program [grant number X8YCBN for the 
Milan study (2006-2009)]; VE was supported by Università degli Studi di Milano ‘Young 
Investigator Grant Program 2017’. 
 25 
References  
 [1] World Health Organization. WHO global report: mortality attributable to tobacco. Geneva: 
WHO; 2012.  
[2] Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F 
(2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for 
Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [21 March 2019].  
 [3] IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 38. 
Tobacco Smoking. Lyon: IARC Press; 1986. 
[4] IARC. IARC Monographs on the evaluation of carcinogenic risks to Humans, Volume 83: 
Tobacco smoke and involuntary smoking. Lyon: IARC Press; 2004. 
[5] Lubin JH, Purdue M, Kelsey K, et al. Total exposure and exposure rate effects for alcohol and 
smoking and risk of head and risk of neck cancer: a pooled analysis of case-control studies. 
Am J Epidemiol 2009;170:937-47. 
[6] Lubin JH, Gaudet MM, Olshan AF, et al. Body mass index, cigarette smoking, and alcohol 
consumption and cancers of the oral cavity, pharynx, and larynx: modeling odds ratios in 
pooled case-control data. Am J Epidemiol 2010;171:1250-61. 
[7] Doll R. An epidemiological perspective of the biology of cancer. Cancer Res 1978;38:3573-83. 
[8] Vlaanderen J, Portengen L, Schüz J, et al. Effect modification of the association of 
cumulative exposure and cancer risk by intensity of exposure and time since exposure 
 26 
cessation: a flexible method applied to cigarette smoking and lung cancer in the SYNERGY 
Study. Am J Epidemiol 2014;179:290-8.  
[9] Lubin JH, Alavanja MC, Caporaso N et al. Cigarette smoking and cancer risk: modeling total 
exposure and intensity. Am J Epidemiol 2007;166:479–89. 
[10] Baris D, Karagas MR, Verrill C, et al. A case-control study of smoking and bladder cancer risk: 
emergent patterns over time. J Natl Cancer Inst 2009;101:1553-61. 
[11] Hashibe M, Brennan P, Benhamou S, et al. Alcohol drinking in never users of tobacco, 
cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in 
the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 
2007;99:777–89. 
[12] Lubin JH, Caporaso NE. Misunderstandings in the misconception on the use of pack-years in 
analysis of smoking. Br J Cancer 2013;108:1218-20.  
[13] Polesel J, Talamini R, La Vecchia C, et al. Tobacco smoking and the risk of upper aero-
digestive tract cancers: A reanalysis of case-control studies using spline models. Int J Cancer 
2008;122:2398–402. 
[14] Desquilbet L, Mariotti F. Dose–response analyses using restricted cubic spline functions in 
public health research. Stat Med 2010;29:1037-57. 
[15] Dal Maso L, Torelli N, Biancotto E, et al. Combined effect of tobacco smoking and alcohol 
drinking in the risk of head and neck cancers: A re-analysis of case-control studies using bi-
dimensional spline models. Eur J Epidemiol 2016;31:385-93.  
 27 
[16] Peto J. That effects of smoking should be measured in pack-years: misconceptions 4. Br J 
Cancer 2012;107:406–7. 
[17] Hashibe M, Brennan P, Chuang S-C, et al. Interaction between tobacco and alcohol use and 
the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer 
Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009;18:541–50. 
[18] Marron M, Boffetta P, Zhang ZF, et al. Cessation of alcohol drinking, tobacco smoking and 
neck cancer risk. Int J Epidemiol 2010;39:182-96. 
[19] Wyss A, Hashibe M, Chuang SC, et al. Cigarette, cigar, and pipe smoking and the risk of head 
and neck cancers: pooled. Am J Epidemiol 2013;178:679–90. 
[20] Franceschi S, Talamini R, Barra S, et al. Smoking and drinking in relation to cancers of the 
oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res 1990;50:6502-7. 
[21] Negri E, La Vecchia C, Franceschi S, Tavani A. Attributable risk for oral cancer in northern 
Italy. Cancer Epidemiol Biomarkers Prev 1993;2:189-93. 
[22] Bosetti C, Gallus, S, Trichopoulou A, et al. Influence of the Mediterranean diet on the risk of 
cancers of the upper aerodigestive tract. Cancer Epidemiol Biomarkers Prev 2003;12:1091-
4.  
[23] Levi F, Pasche C, La Vecchia C, Lucchini F, Franceschi S, Monnier P. Food groups and risk 
of oral and pharyngeal cancer. Int J Cancer 1998;77:705-9. 
 28 
[24] Hashibe M, Boffetta P, Zaridze D. Evidence for an important role of alcohol- and aldehyde-
metabolizing genes in cancers of the upper aerodigestive tract. Cancer Epidemiol 
Biomarkers Prev 2006;15:696-703. 
[25] Muscat JE, Richie JP Jr., Thompson S, Wynder EL. Gender differences in smoking and risk 
for oral cancer. Cancer Res 1996;56:5192-7. 
[26] Rosenblatt KA, Daling JR, Chen C, Sherman KJ, Schwartz SM. Marijuana use and risk of 
oral squamous cell carcinoma. Cancer Res 2004;64:4049-54. 
[27] Smith EM, Hoffman HT, Summersgill KS, Kirchner HL, Turek LP, Haugen TH. Human 
papillomavirus and risk of oral cancer. Laryngoscope1998;108:1098-103. 
[28] Olshan AF, Weissler MC, Watson MA, Bell DA. GSTM1, GSTT1, GSTP1, CYP1A1, and 
NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol 
Biomarkers Prev 2000;9:185-91. 
[29] Elahi A, Zheng Z, Park J, Eyring K, McCaffrey T, Lazarus P. The human OGG1 DNA repair 
enzyme and its association with orolaryngeal cancer risk. Carcinogenesis 2002;23:1229-34. 
[30] Cui Y, Morgenstern H, Greenland S, et al. Polymorphism of xeroderma pigmentosum group 
G and the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx and 
esophagus. Int J Cancer 2006;118:714-20. 
[31] Zhang Z, Shi Q, Liu Z, Sturgis EM, Spitz MR, Wei Q. Polymorphisms of methionine synthase 
and methionine synthase reductase and risk of squamous cell carcinoma of the head and 
neck: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2005;14:1188-93. 
 29 
[32] Hayes RB, Bravo-Otero E, Kleinman DV, et al. Tobacco and alcohol use and oral cancer in 
Puerto Rico. Cancer Causes Control 1999;10:27-33. 
[33] Szymańska K, Hung RJ, Wünsch-Filho V, et al. Alcohol and tobacco, and the risk of cancers 
of the upper aerodigestive tract in Latin America: a case-control study. Cancer Causes 
Control 2011;22:1037-46. 
[34] Herrero R, Castellsagué X, Pawlita M, et al. IARC Multicenter Oral Cancer Study Group. 
Human papillomavirus and the risk of Human papillomavirus and oral cancer: the 
International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 
2003;95:1772-1783. 
[35] Peters ES, McClean MD, Liu M, Eisen EA, Mueller N, Kelsey KT. The ADH1C polymorphism 
modifies the risk of squamous cell carcinoma of the head and neck associated with alcohol 
and tobacco use. Cancer Epidemiol Biomarkers Prev 2005;14:476-82. 
[36] Gallì P, Cadoni G, Volante M, et al. A case-control study on the combined effects of p53 and 
p73 polymorphisms on head and neck cancer risk in an Italian population. BMC Cancer  
2009;9:137. 
[37] Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and 
pharyngeal cancer. Cancer Res 1988;48:3282. 
[38] Boing AF, Ferreira Antunes JL, de Carvalho MB, et al. How much do smoking and alcohol 
consumption explain socioeconomic inequalities in head and neck cancer risk? J Epidemiol 
Community Health 2010;65:709-14. 
 30 
[39] Schantz SP, Zhang ZF, Spitz MS, Sun M, Hsu TC. Genetic susceptibility to head and neck 
cancer: interaction between nutrition and mutagen sensitivity. Laryngoscope 1997;107:765-
81. 
[40] Rogers MA, Thomas DB, Davis S, Vaughan TL, Nevissi AE. A case-control study of element 
levels and cancer of the upper aerodigestive tract. Cancer Epidemiol Biomarkers Prev 
1993;2:305-12. 
[41] Lagiou P, Georgila C, Minaki P, et al. Alcohol-related cancers and genetic susceptibility in 
Europe: the ARCAGE project: study samples and data collection. Eur J Cancer Prev 
2009;18:76-84. 
[42] Anderson KS, Gerber JE, D’Souza G, et al. Biologic predictors of serologic responses to 
HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncol 2015;51:751-8. 
[43] Twardella D, Loew M, Rothenbacher D, Stegmaier C, Ziegler H, Brenner H. The diagnosis of 
a smoking-related disease is a prominent trigger for smoking cessation in a retrospective 
cohort study. J Clin Epidemiol 2006;59:82-9. 
[44] Dietz A, Ramroth H, Urban T, Ahrens W, Becher H. Exposure to cement dust, related 
occupational groups and laryngeal cancer risk: results of a population based case-control 
study. Int J Cancer 2004;108:907-11. 
[45] Suzuki T, Wakai K, Matsuo K, et al. Effect of dietary antioxidants and risk of oral, pharyngeal 
and laryngeal squamous cell carcinoma according to smoking and drinking habits. Cancer 
Sci 2006;97:760-7. 
 31 
[46] Divaris K, Olshan AF, Smith J, et al. Oral health and risk for head and neck squamous cell 
carcinoma: the Carolina Head and Neck Cancer Study. Cancer Causes Control  
2010;21:567-75. 
[47] Menvielle G, Luce D, Goldberg P, Leclerc A. Smoking, alcohol drinking, occupational 
exposures and social inequalities in hypopharyngeal and laryngeal cancer. Int J Epidemiol 
2004;33:799-806. 
[48] Jayaprakash V, Rigual NR, Moysich KB et al. Chemoprevention of Head and Neck Cancer 
With Aspirin. Arch Otolaryngol Head Neck Surg  2006;132:1231-6. 
[49] Luce D, Stücker I. ICARE Study Group. Investigation of occupational and environmental 
causes of respiratory cancers (ICARE): a multicenter, population-based case-control study in 
France. BMC Public Health  2011;11:928. 
[50] D'souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papilloma virus and 
oropharyngeal cancer. N Engl J Med 2007;10;356:1944-56. 
[51] Zheng TZ, Boyle P, Hu HF, et al. Dentition, oral hygiene, and risk of oral cancer: a case-
control study in Beijing, People's Republic of China. Cancer Causes Control 1990;1:235-41. 
[52] Bravi F, Bosetti C, Filomeno M, et al. Foods, nutrients and the risk of oral and pharyngeal 
cancer. British Journal of Cancer 2013;109:2904-10. 
[53] Lubin JH, Kogevinas M, Silverman D, et al. Evidence for an intensity-dependent interaction of 
NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study. Int J 
Epidemiol 2007;36:236-41.  
 32 
[54] Ruppert D, Wand M, Carroll R. Semiparametric Regression (Cambridge Series in Statistical 
and Probabilistic Mathematics). Cambridge: Cambridge University Press; 2003. 
[55] Di Credico G. Some developments in semiparametric and cross-classified multilevel models. 
Ph.D. Thesis. Padua University: Italy; 2018 
[56] Gelman A, Stern HS, Carlin JB, Dunson DB, Vehtari A, Rubin DB. Bayesian Data 
Analysis. Chapman and Hall/CRC; 2013. 
[57] Gelman A, Jakulin A, Pittau MG, Su YS. A weakly informative default prior distribution for 
logistic and other regression models. Ann Appl Stat 2008;2:1360-83. 
[58] Hoffman MD, Gelman A. The No-U-turn sampler: adaptively setting path lengths in 
Hamiltonian Monte Carlo. J Mach Learn Res 2014;15:1593-623. 
[59] Watanabe S.  Asymptotic equivalence of Bayes cross validation and widely applicable 
information criterion in singular learning theory. J Mach Learn Res 2010;11:3571-94. 
[60] Gelman A, Hwang J, Vehtari, A. Understanding predictive information criteria for Bayesian 
models. Stat Comput 2014;24:997-1016. 
[61] Stan Development Team. Stan Modeling Language Users Guide and Reference Manual. 
Version 2.17.0, 2017. 
[62] Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph 
Stat 1996;5:299-314. 
[63] R Development Core Team. R: A language and environment for statistical 
computing. R Foundation for Statistical Computing. Vienna: Austria; 2018.  
 33 
[64] Berthiller J, Straif K, Agudo A, et al. Low frequency of cigarette smoking and the risk of head 
and neck cancer in the INHANCE consortium pooled analysis. Int J Epidemiol 2016;45:835-45.  
[65] Zuo JJ, Tao ZZ, Chen C, et al. Characteristics of cigarette smoking without alcohol 
consumption and laryngeal cancer: overall and time-risk relation. A meta-analysis of 
observational studies. Eur Arch Otorhinolaryngol 2017;274:1617-31. 
[66] Molinari N, Durand JF, Sabatier R.  Bounded optimal knots for regression splines. Comput Stat 
Data Anal 2004;45:159–78. 
[67] Mao W, Zhao LH. Free-knot polynomial splines with confidence intervals. J R Statist Soc B 
2003;65( Part 4):901–19. 
[68] Schöllnberger H, Manuguerra M, Bijwaard H, et al. Analysis of epidemiological cohort data on 
smoking effects and lung cancer with a multi-stage cancer model. Carcinogenesis 
2006;27:1432-44.  
[69] Caraballo RS, Giovino GA, Pechacek TF, Mowery PD. Factors associated with discrepancies 
between self-reports on cigarette smoking and measured serum cotinine levels among 
persons aged 17 years or older: Third National Health and Nutrition Examination Survey, 
1988-1994. Am J Epidemiol 2001;153:807-14. 
[70] Morales NA, Romano MA, Michael Cummings K, et al. Accuracy of self-reported tobacco use 
in newly diagnosed cancer patients. Cancer Causes Control 2013;24:1223-30. doi: 
10.1007/s10552-013-0202-4. 
 34 
[71] Rothman KJ, Greenland S, Lash T. Modern epidemiology. Third Edition. Philadelphia: 
Lippincott Williams & Wilkins; 2008; pp. 303-27. 
 35 
Figure captions 
Figure 1 - Flow chart of subjects’ selection 
 
Figure 2 - Odds ratiosa,b of oral and pharyngeal cancer and laryngeal cancer in current 
smokers, for the joint effect of intensity (cigarettes/day) and duration (years) of cigarette 
smoking estimated through bivariate spline models. INHANCE consortium 
 
a Fitted models included adjustment for age, sex, race, study, education, drinking status, drinking 
intensity, and drinking duration. The reference category was defined as ‘‘Never smokers’’. b On 
the grid, black thicker lines represent knot locations: 16 cigarettes/day and 33 years of duration 
for oral and pharyngeal cancer and 25 cigarettes/day and 30 years of duration for laryngeal 
cancer, respectively. Dark grey lines in contour plots indicate iso-risk curves at defined levels of 
risk. 
 
Figure 3 - Odds ratiosa,b of oral and pharyngeal cancer in current smokers by alcohol 
drinking intensity, for the joint effect of intensity (cigarettes/day) and duration (years) of 
cigarette smoking, estimated through bivariate spline models. INHANCE consortium 
 
a Fitted models included adjustment for age, sex, race, study, education, and alcohol drinking 
status. The reference category was defined as ‘‘Never smokers’’, in each strata of alcohol 
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drinking intensity. b On the grid, black thicker lines represent knot locations: 32 years of duration 
for never drinkers, and 12 cigarettes/day and 25 years of duration for heavy drinkers, respectively. 
Dark grey lines in contour plots indicate iso-risk curves at defined levels of risk. 
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Figure 4 - Odds ratioa,b of oral and pharyngeal cancer and laryngeal cancer in former 
smokers who quit ≥10 years ago, for the joint effect of intensity (cigarettes/day) and 
duration (years) of cigarette smoking estimated through bivariate spline models. 
INHANCE consortium 
 
a Fitted models included adjustment for age, sex, race, study, education, drinking status, 
drinking intensity, and drinking duration. The reference category was defined as ‘‘Never 
smokers’’. b On the grid, the black thicker line represents the knot location: 27 cigarettes/day 
for laryngeal cancer. Dark grey lines in contour plots indicate iso-risk curves at defined levels 
of risk. 
 
